Bioprosthetic or mechanical heart valves : prosthesis choice for borderline patients?-Results from 9,616 cases recorded in Polish national cardiac surgery registry by Bartuś, Krzysztof et al.
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(10):5869-5878 | http://dx.doi.org/10.21037/jtd-19-3586
Original Article
Bioprosthetic or mechanical heart valves: prosthesis choice for 
borderline patients?—Results from 9,616 cases recorded in Polish 
national cardiac surgery registry
Krzysztof Bartus1, Radosław Litwinowicz1, Jerzy Sadowski1, Grzegorz Filip1, Mariusz Kowalewski2,  
Piotr Suwalski2, Piotr Mazur1, Anna Kędziora1, Marek Jasiński3, Marek Deja4, Mariusz Kuśmierczyk5, 
Pawel Czub6, Michal Zembala7,8, Marek Jemielity9, Rafał Pawlaczyk10, Zdzisław Tobota11,  
Bohdan Maruszewski11, Boguslaw Kapelak1
1Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, John Paul II Hospital, Krakow, Poland; 2Clinical Department 
of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland; 3Department of Cardiac Surgery, 
University Hospital in Wroclaw, Wroclaw Medical University, Wroclaw, Poland; 4Department of Cardiac Surgery, Medical University of Silesia, 
Katowice, Poland; 5Department of Cardiosurgery and Transplantology, The Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland; 
6Department of Cardiac Surgery, Medical University of Warsaw, Warsaw, Poland; 7Silesian Center for Heart Disease, Zabrze, Poland; 8Department 
of Cardiac Surgery, Vascular Surgery and Transplantology Silesian Medical University Katowice, Katowice, Poland; 9Department of Cardiac Surgery 
and Transplantology, University Hospital of Lord Transfiguration, Poznan University of Medical Sciences, Poznan, Poland; 10Department of Cardiac 
Surgery, Medical University of Gdansk, Gdansk, Poland; 11Department for Pediatric Cardiothoracic Surgery, Children’s Memorial Health Institute, 
Warsaw, Poland
Contributions: (I) Conception and design: K Bartus, R Litwinowicz; (II) Administrative support: R Litwinowicz, P Mazur, A Kedziora, G Filip; (III) 
Provision of study materials or patients: M Kowalewski, G Filip, M Jasinski, M Dejak, M Kusmierczyk, S Pawlak, M Jemielity, D Jagielak, P Hendzel, 
P Suwalski, Z Tobota, B Maruszewski, B Kapelak; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; 
(VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Radoslaw Litwinowicz, MD, PhD. Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, JP II 
Hospital, ul. Pradnicka 80, 31-202 Krakow, Poland. Email: md.litwinowicz@gmail.com. 
Background: In middle-aged patients undergoing aortic valve replacement (AVR), the selection of 
prosthesis type is a complex process. Current guidelines do not unequivocally indicate the type of prosthesis 
(bioprosthetic or mechanical) recommended for patients between 60–70 years of age. The aim of the study 
was to present the trends in AVR prosthesis selection in borderline patients over a 10-year period, based on 
real-life registry data. 
Methods: The study population comprised of 9,616 consecutive patients aged between 60–70 years, who 
underwent isolated AVR between 2006 and 2016 in all cardiac surgery departments in Poland. Data were 
extracted from the Polish National Registry of Cardiac Surgery.
Results: Among 27,797 consecutive AVR procedures, patients aged 60–70 years represented 34.6% of the 
population operated on. From 2006 to 2016, bioprosthetic valves (BVs) were implanted in 53.9% cases, (and) 
mechanical valves (MVs) in 42.1%. The proportion of different valve types changed in time: from 77.5% of 
MVs vs. 22.5% of BVs in 2006 to 23.2% of MVs vs. 76.8% of BVs in 2016 (P<0.001). The most commonly 
implanted BV was the Hancock II (used in 36.4% of BV implantations), the most commonly used MV was 
the Saint Jude Mechanical prosthesis (implanted in 36.4% of MV implantation cases). A multivariable model 
identified smaller annulus [OR (95% CI) 0.89 (0.86–0.92), P<0.001], atrial fibrillation [OR (95% CI) 1.32 
(1.05–1.67), P=0.017], male sex [OR (95% CI) 1.47 (1.24–1.74), P<0.001] and year of implantation [OR (95% 
CI) 0.75 (0.71–0.79), P<0.001] as predictors of MV implantation.
Conclusions: Patients aged 60–70 years represent more than one-third of all AVR patients. Between 2006 
and 2016, the proportion of implanted prostheses has changed dramatically. In 2016 BVs were implanted in 
nearly 75% of AVR cases, three times more often than in 2006. 
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Introduction
Middle-aged patients are healthier, have fewer comorbidities 
and a lower risk of operation compared to the older 
population. Therefore, in middle-aged patients surgical 
aortic valve replacement (AVR) is still the gold standard 
for treating aortic stenosis, while transcatheter aortic valve 
implantation (TAVI) is reserved for older patients, with 
higher risk for poor surgical outcome (1,2).
The advantages and disadvantages of mechanical valves 
(MV) and bioprosthetic valves (BV) are well known (1-5). 
In middle-aged patients, both prosthesis-related factors 
and patient preferences should be taken into account, when 
choosing the type of valve prosthesis. Prosthesis selection is 
oftentimes difficult and requires a complex decision-making 
process, especially in patients aged between 60–70 years. 
For this group of patients, the recommendations are vague 
or lacking. Current ESC/EACTS guidelines recommended 
a bioprosthesis in aortic position for individuals <60 years 
of age, while bioprosthesis is recommended in patients 
>65 years old (both, class IIa recommendation, level 
of evidence C) (1). AHA/ACC guidelines suggest MV 
selection for patients as young as <50 years of age (class IIa 
recommendation, level of evidence B) (2). Hence, prosthesis 
selection in patients aged 60–70 years is backed with 
insufficient evidence, difficult, and made on case-by-case basis.
We present the following article in accordance with the 
5-STROBE guideline checklist (available at http://dx.doi.
org/10.21037/jtd-19-3586). 
The aim of the study was to present time-related 
trends in elective surgical AVR in patients aged between 
60–70 years old, based on 9,616 cases from a multicentre 
Poland registry. Ten-year trends were assessed by comparing 
patient characteristics, distribution of risk factors, aortic 




The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). This study 
used retrospective data from the obligatory Polish National 
Cardiac Surgery Database (“KROK” registry; www.
krok.csioz.gov.pl). The Polish Society of Cardiothoracic 
Surgeons approved this project. All data has been 
anonymized, and the need to obtain individual patient 
consents has been waived. The registry is an ongoing, 
nationwide, multi-institutional registry of cardiosurgical 
procedures in Poland and an initiative of the Club of Polish 
Cardiac Surgeons in cooperation with the Polish Ministry 
of Health that commenced in 2006 and collects data from 
all 37 heart surgery centers in Poland (a list of contributing 
centers is provided in the Acknowledgment section at the 
end of the article). Centers enrolling patients into the 
KROK registry are required to transfer the data concerning 
every cardiac surgery to the central database in the National 
Centre for Healthcare Information Systems at the Ministry 
of Health and are financially liable for data integrity and 
completeness. A registry module for collecting the data 
regarding myocardial infarctions (MIs), hospitalizations due 
to unstable angina, subsequent revascularizations, strokes, 
and other complications was under construction at the time 
of analysis (6).
Study databases
A detailed questionnaire, defined according to standard 
definitions, including demographic data, previous medical 
history, on-admission physical findings, pharmacological 
management, and outcomes, was developed. Data were 
collected either at presentation or by physician review of the 
hospital records and were forwarded to the KROK registry. 
The forms were reviewed for clinical face validity and 
analytical internal validity. On the basis of the form of the 
National Registry of Cardiac Surgery (KROK), a computer 
database was built for statistical analysis. 
Study population and clinical variables
Using the KROK database, we identified patients who 
underwent isolated AVR as the first cardiosurgical 
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intervention between January 2006 and August 2016. 
Patients who had previous cardiac surgery were excluded 
from the study. Among 27,97 consecutive adult patients who 
underwent isolated surgical AVR during the studied period 
10,343 patients were aged between 60–70 years (37.2%). 
We excluded the records, where the type of prosthesis was 
not reported and not retrievable (9.1%), resulting in a final 
cohort of 9,616 patients (34.6%). For patients undergoing 
AVR, we collected: baseline demographic characteristics 
[age, gender, European system for cardiac operative risk 
evaluation (EuroSCORE) score, diabetes, body mass, 
hypertension, pulmonary hypertension, chronic kidney 
disease, extracardiac arteriopathy, chronic lung disease, left 
ventricle ejection fraction (LVEF), Canadian Cardiovascular 
Society, and New York Heart Association functional class], 
aortic valve pathology, preoperative aortic gradients,, 
extracorporeal circulation time, aortic cross clamping time, 
time in the intensive care unit (ICU), total hospitalization 
time, in hospital mortality and time of death after surgery. 
In-hospital mortality was defined as death up to 30 days 
after the procedure. The authors had full access to the data, 
take responsibility for its integrity, and have read and agree 
to the manuscript as written. 
Statistical analysis
Continuous variables were checked for normal distribution 
with the Kolmogorov-Smirnov test. Data expressed as 
mean ± standard deviation or median (interquartile range), 
unless otherwise stated elsewhere. Categorical variables 
were expressed as count and percentage, and compared with 
the chi-square test. The consecutive years were treated as 
an ordinal variable and the Kolmogorov-Smirnoff test was 
performed to confirm the difference in the implanted valve 
type within consecutive years. The Poisson regression was 
created to estimate the impact of the consecutive years on 
the numerical amount of mechanical valves implantations 
represented as a percentage of total valve implantations 
within each year. Differences in age between patients each 
year were calculated using Friedman test, followed by post-
hoc Dunnett C analysis to assess the maximum differences. 
Multivariable regression model was created to confirm the 
independent impact of the surgery year on the implanted 
valve type. The model was standardized for EuroSOCRE 
I, sex, BMI, endocarditis as an indication for AVR, history 
of atrial fibrillation, and the size of the implanted valve as 
an expression of the annulus size. Statistical analysis was 
performed with STATISTICA 10.0 (StatSoft, Tulsa, OK, 




A total of 9,616 patients aged between 60–70 years were 
studied. The caseload increased significantly from 630 cases 
performed in 2006 to 1,184 cases performed in 2015 (Figure 1). 
Detailed patient characteristics are presented in Table 1. 
From 2006 to 2016, BVs were implanted in 53.9% cases, 
MVs in 42.1% cases. Regarding BVs, 89.5% of implanted 
prostheses were stented valves. There were no differences 
in mean transaortic gradients between BV and MV groups. 











2006      2007     2008     2009      2010     2011      2012     2013      2014      2015    2016*
 630        574       696        762       817       893         965      997       1089      1187      699
3.65%  4.70%   2.16%   3.41%   2.45%   3.58%   3.32%   3.21%   4.22%   3.45%   1.86%
*2016-data collected from 1st January to 31st August 2016
Figure 1 Number of cases and mortality of surgical AVR performed in each year. 
5872 Bartus et al. Prosthesis selection in borderline patients over the last 10 years
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(10):5869-5878 | http://dx.doi.org/10.21037/jtd-19-3586
Table 1 Patient characteristics, valve pathology and operative data
Variables Biological (n/N=5,191/5,191)* Mechanical (n/N=4,425/4,425)* P
Age 65.7 (63/67) (5,191/5,191) 63.9 (61/66) (4,425/4,425) 0.005
Gender 0.005
Female 41.1% (2,133/5,191) 37.6% (1,664/4,425)
Male 58.9% (3,058/5,191) 62.4% (2,761/4,425)
BMI, kg/m2 28.7 (25.4/31.5) (4,947/5,191) 28.6 (25.3/31.4) (4,305/4,425) 0.9625
Euro SCORE 1.8 (0.8/1.8) (5,191/5,191) 1.4 (0.7/1.4) (4,425/4,425) 0.0001
LVEF (%) 55 (48/60) (4365/5,191) 55 (48/60) (3,509/4,425) 0.2369
CCS 0.0071
CCS 0 26.3% (1,599/5,086) 30.7% (1,341/4,370)
CCS 1 24.1% (1,466/5,086) 27.7% (1,210/4,370)
CCS 2 25.1% (1,527/5,086) 32.4% (1,416/4,370)
CCS 3 7.4% (449/5,086) 7.8% (342/4,370)
CCS 4 0.1% (45/5,086) 1.4% (61/4,370)
NYHA 0.0045
NYHA 0 4.5% (230/5,118) 3.4% (149/4,371)
NYHA 1 9.9% (507/5,118) 8.8% (383/4,371)
NYHA 2 47.1% (2,417/5,118) 47.7% (2,087/4,371)
NYHA 3 34.6% (1,772/5,118) 35.2% (1,538/4,371)
NYHA 4 3.6% (185/5,118) 4.7% (204/4,371)
Acute HF 0.2% (12/5,118) 0.2% (10/4,371)
Hyperlipidaemia 48.5% (2,464/5,077) 44.7% (1,956/4,376) 0.0002
Hypertension 78.2% (3,994/5,051) 75.6% (3,308/4,376) 0.0022
Atrial fibrillation 9.9% (502/5,105) 12.1% (516/4,233) 0.0006
Chronic lung disease 7.3% (361/4,975) 6.7% (516/4,218) 0.304
Diabetes insulin dependent 7.1% (362/5,089) 6.6% (290/4,381) 0.3651
Renal impairment
Normal (CC >85 mL/min) 59.6% (1,835/3,081) 59.3% (881/1,486)
Moderate (CC >50 & <85) 36.1% (186/3,081) 35.3% (525/1,486) 0.1786
Severe (CC <50) 3.9% (119/3,081) 4.4% (66/1,486)
Dialysis (regardless of CC) 0.5% (14/3,081) 0.9% (14/1,486)
Pulmonary hypertension 0.334
Severe (>55 mg) 0.9% (28/3,087) 1.1% (16/1,520)
Moderate (31–55 mmHg) 6.0% (186/3,087) 5.0% (76/1,520)
None 93.1% (2,873/3,087) 93.9% (1,428/1,520)
Table 1 (continued)
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Table 1 (continued)
Variables Biological (n/N=5,191/5,191)* Mechanical (n/N=4,425/4,425)* P
Extracardiac arteriopathy 10.2% (455/4,016) 7.4% (234/3,154) 0.0001
Smoking 0.4521
Active smoker 10.2% (513/5,037) 9.9% (415/4,201)
Former smoker  41.8% (2,107/5,037) 40.8% (1,715/4,201)
Never smoker 48.0% (2,417/4,201) 49.3% (2,071/4,201)
Max. aortic gradients (mmHg) 85 (70/100) (4,076/5,051) 86 (69/100) (3,353/4,425) 0.1025
Implant prosthesis size 0.0001
17 mm 0.02% (1/5,149) 0.2% (11/4,225)
19 mm 3.5% (181/5,149) 10.5% (442/4,225)
21 mm 26.8% (1,381/5,149) 27.9% (1,178/4,225)
23 mm 37.9% (1,954/5,149) 35.2% (1,488/4,225)
25 mm 21.3% (1,096/5,149) 18.3% (773/4,225)
27 mm 8.0% (412/5,149) 5.8% (247/4,225)
29 mm 2.3% (121/5,149) 1.7% (70/4,225)
31 mm 0.06% (3/5,149) 0.4% (15/4,225)
33 mm 0.02% (1/5,149) 0.02% (1/4,225)
ECC time (min) 93 (77/117) (5,029/5,191) 97 (79/122) (4,333/4,425) 0.0001
ACC (min) 65 (54/81) (4,109/5,191) 97 (79/122) (4,333/4,425) 0.0001
Time on ICU (day) 2 (1/2) (4,927/5,191) 2 (1/3) (4,223/4,425) 0.8700
Hospitalization (day) 9 (8/13) (5,133/5,191) 10 (8/14) (4,393/4,425) 0.0793
In hospital mortality 3.4% (175/5,191) 3.1% (132/4,425) 0.307
Time of death after surgery (day) 7 (3/14) (175/5,191) 6 (2/12) (132/4,425) 0.0359
*, (n/N): number of records/total number of available records. ACC, Aortic Cross Clamp; BMI, body mass index; CC, creatinine clearance; 
CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; ECC, extracorporeal circulation; NYHA, New York 
Heart Association. 
was degenerative aortic stenosis. The proportion of 
prosthetic valves changed throughout time from 77.5% of 
MVs vs. 22.5% of BVs in 2006, to 23.2% of MVs vs. 76.8% 
of BVs in 2016 (P<0.001; Figure 2). The most commonly 
implanted prosthesis size was 23 mm in both groups. 
Prosthesis size ≤19 mm was observed in 3.5% cases of BV, 
and in 10.7% cases of MV implantation (P<0.001). The 
most common bioprosthesis was the Hancock II implant, 
used in 36.4% BV cases, and the most commons mechanical 
prosthesis was Saint Jude Mechanical implant, used in 
42.4% (Figure 3). There were no differences between BV 
and MV in in-hospital mortality over the analysed period of 
time within each consecutive year.
The MV was implanted more often in case of a smaller 
annulus, atrial fibrillation, and male sex. The odds of MV 
implantation decreases decreased by almost 25% each year, 
regardless of other significant factors (Figure 4). 
Discussion
Aortic valve surgery is the second most common type of 
cardiac surgery in Poland and worldwide, and with the 
ageing of the population, it is anticipated that the number 
of surgical AVR procedures, despite the progress of 
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2006       2007       2008      2009       2010       2011       2012       2013      2014       2015       2016
Year
Figure 2 Type of prosthesis implanted in each year. 
Figure 3 Proportion of all implanted prostheses in each year. (A) Biological prosthesis; (B) mechanical prosthesis. *, all type of prosthesis 
whose frequency <1%. 
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MALE SEX 1.474 <0.001 1.246 1.743
ENDOCARDITIS 1.174 0.404 0.806 1.709
ATRIAL FIBRILATION 1.328 0.017 1.052 1.675
PROTHESIS SIZE 0.888 <0.001 0.857 0.920
YEAR OF THE SURGERY 0.753 <0.001 0.710 0.798
EUROSCORE I 0.998 0.840 0.978 1.018
BMI 1.012 0.120 0.997 1.026
Odds ratio
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percutaneous procedures, will continue growing (1,2,5,7-10). 
In the 2017 ACC/AHA guidelines, isolated AVR is still 
the gold standard treatment for aortic stenosis in low and 
moderate risk patients (Class I) and is recommended as 
an alternative to TAVI in high risk patients (Class I) (2). 
Therefore, TAVI procedures are mainly performed in 
older groups of patients with a high risk of poor surgical 
outcomes. In middle-aged patients, presenting lower 
operative risk and fewer comorbidities, surgical AVR 
remains the main treatment option (9).
Currently, when replacing the aortic valve, a plethora 
of prostheses is available (1-5,7), yet the decision comes 
down to choosing between a BV or an MV (4,11-14). 
Unfortunately, the selection of prosthesis type is complex. 
BVs (stented or stentless porcine bioprostheses, stented 
pericardial prostheses) have the advantage of not requiring 
lifelong warfarin therapy due to their lower thrombotic 
risk and significantly decreased risk of bleeding, with 
the disadvantage of shorter durability (4,11-13,15). MVs 
(bileaflet or monoleaflet) are partly constructed with 
pyrolytic carbon, which provides longer durability, but the 
disadvantages include an increased thromboembolic risk, 
thus requiring anticoagulation with warfarin and resulting in 
elevated risk of bleeding (16,17). The most recently updated 
guidelines point to patient age at the time of implantation 
as one of the pivotal factors in decision-making process: in 
younger patients (<60 by ESC/EACTS and <50 by AHA/
ACC), in whom there is no contraindication for warfarin 
therapy, a MV is advocated by guidelines (1,2). BVs are 
recommended in older patients: >65 years old in ESC/
EACTS, and >70 years in AHA/ACC guidelines (the grey 
zone being even wider in the American guidelines) (1,2). 
Middle-aged (60–70 years old) patients present a 
particular challenge due to the important considerations of 
longer life expectancy and potentially more active lifestyle, 
compared with older patients. The scale of the problem is 
considerable—our study showed that more than 34% of all 
patients undergoing AVR are borderline cases. Moreover, 
the number of patients operated on in this age group has 
been steadily increasing, from 607 cases in 2006 to 1,187 in 
2015.
Strong recommendations, backed by unequivocal 
evidence, are lacking for middle-aged patients, and 
careful decision-making, considering individual patient 
characteristics and preferences, is warranted in each 
case. Cardiac surgeons are responsible for guiding the 
patient through this difficult decision-making process. 
Our results showed that surgeons implanted BV more 
often in females, in patients with higher EuroSCORE and 
patients without atrial fibrillation. The first generation of 
bioprostheses had increased rates of re-operation due to 
structural valve deterioration, which is a major obstacle, 
especially in younger patients. However, newer generations 
bioprostheses, with good hemodynamic characteristics 
and novel methods of preservation, achieve durability 
comparable to mechanical prostheses (11,13). A large meta-
analysis including patients between 40 and 70 years old 
showed that there was no significant difference in survival up 
to 15 years, based on prosthesis type; the major differences 
were observed after 20–25 years of observation (13). 
However,  one study has reported non-significant 
differences in 20 and 25-year outcomes in patients under 
60 years old (18). Mortality associated with re-operation 
is becoming low and acceptable, and may be even lower 
than mortality associated with major bleeding, resulting 
from anticoagulation (12,13). Therefore, MVs were chosen 
more often in patients with AF, already receiving oral 
anticoagulation. 
The factor that has revolutionized the approach to 
biological valves over the last decade was the development 
of TAVI. In Poland, the number of TAVI procedures and 
TAVI-capable centers is constantly growing. While in the 
early years of the analysed period the increase in the use of 
BVs might have resulted solely from increasing availability 
of BV on the Polish market, the role of TAVI might be 
increasingly important in the more recent years. In authors’ 
opinion, the possibility of avoiding any re-operation by 
means of percutaneous valve-in-valve procedure in high risk 
patients is a major factor that caused increased percentage 
of implanted BVs (1,2). 
Compared to BVs, MVs were more often implanted in 
patients with smaller annulus. MVs present higher index 
of effective orifice area than BVs, therefore the risk of 
postoperative patients prosthesis mismatch is lower. Smaller 
prosthesis size, ≤19 mm, which have a higher risk of post-
operative prosthesis mismatch, were implanted only in 3.5% 
of patients with BVs and in 10.7% of patients with MVs 
(19,20). The most common prosthesis size was 23 mm in 
both the MVs and BVs groups, and similar to the general 
AVR group (7,21). 
The studied cohort of patients aged 60–70 years in this 
report was demographically and clinically similar to other 
AVR cohorts from database studies (7,21). 
Our study presents a clinically and practically important 
trend change in aortic valve surgery in the borderline 
patients, comprising 1/3 of all individuals operated on for 
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aortic valve pathology. An increased rate of BV implantation 
has been observed in the last decade (7,21,22). However, 
other databases present higher percentages of implantation 
procedures in each year in general population, likely a 
reflection of the aortic valve surgery in the central-eastern 
Europe. Brown et al. (22) reported a 78.4% rate of BV 
implantation in 2006 and Thourani et al. (7) 83.8% in 2010 
in United States and Dunning et al. (21) 78% in 2009 in 
Great Britain and Ireland. However, these data present 
results of patients in different age groups. It should be also 
noted that Polish AVR patients are younger, compared to 
other Western countries. Therefore, in older population 
groups in other studies, there is also a higher prevalence of 
BV than observed in the present study. Independently of 
this difference, it should be noted that the percentage of 
implanted MVs in Poland is still high. 
From nearly ten thousand aortic valve prostheses 
implanted during the study period in Poland in middle-aged 
patients, the most common implanted prosthesis was the 
Hancock II made from porcine aortic valves. The second 
most implanted prosthesis was the Saint Jude Mechanical 
Valve. The results showed that in a country where there 
are 37 cardiac surgery centers, there is significant variety in 
the different therapeutic valve options, including stented, 
stentless, sutureless, and mechanical valves (3,23-25). 
However, we did not assess the effect of valve type on 
operative outcomes, as the preferred valves change over 
time, as newer models are released.
In the last 10 years, in-hospital mortality in middle-
aged patients was 3.3%, and was comparable with results 
from American or British databases. Advances in pre- and 
postoperative care have reduced serious postoperative 
complications (26,27). 
Study limitations 
This study has several limitations. Firstly, the information 
on the EuroSCORE II and STS score is lacking. The 
EuroSCORE was replaced by EuroSCORE II in 2011. In 
Poland, different centres replaced their scoring systems 
at different times. Therefore, we decided to present only 
EuroSCORE I results. Secondly, in some cases medical 
data are incomplete (number of missing cases is reported 
for each variable). However, because of the large number of 
patients in our database (50,846 cases), these omissions were 
unlikely to affect the overall study findings. Thirdly, this 
study has all of the limitations of collection of data from 37 
centres.
Conclusions
Middle-aged patients aged between 60–70 years old 
represent more than one-third of all AVR patients. In 
Poland, the use of valve subtypes has changed over the 
last ten years due to availability of BVs. In 2016, BVs were 
implanted in more than 77% of AVR cases, three times 
more often than in 2006. In-hospital mortality was 3.3%.
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